113 related articles for article (PubMed ID: 21454190)
1. Copy number variations of EphA3 are associated with multiple types of hematologic malignancies.
Guan M; Liu L; Zhao X; Wu Q; Yu B; Shao Y; Yang H; Fu X; Wan J; Zhang W
Clin Lymphoma Myeloma Leuk; 2011 Feb; 11(1):50-3. PubMed ID: 21454190
[TBL] [Abstract][Full Text] [Related]
2. Analysis of copy number variations of BS69 in multiple types of hematological malignancies.
Yang H; Zhang C; Zhao X; Wu Q; Fu X; Yu B; Shao Y; Guan M; Zhang W; Wan J; Huang X
Ann Hematol; 2010 Oct; 89(10):959-64. PubMed ID: 20425112
[TBL] [Abstract][Full Text] [Related]
3. The association between the copy-number variations of ZMAT4 and hematological malignancy.
Wan J; Gao Y; Zhao X; Wu Q; Fu X; Shao Y; Yang H; Guan M; Yu B; Zhang W
Hematology; 2011 Jan; 16(1):20-3. PubMed ID: 21269563
[TBL] [Abstract][Full Text] [Related]
4. Examination of copy number variations of CHST9 in multiple types of hematologic malignancies.
Zhao X; Wu Q; Fu X; Yu B; Shao Y; Yang H; Guan M; Huang X; Zhang W; Wan J
Cancer Genet Cytogenet; 2010 Dec; 203(2):176-9. PubMed ID: 21156230
[TBL] [Abstract][Full Text] [Related]
5. Investigation of copy-number variations of C8orf4 in hematological malignancies.
Zhang J; Gao Y; Zhao X; Guan M; Zhang W; Wan J; Yu B
Med Oncol; 2011 Dec; 28 Suppl 1():S647-52. PubMed ID: 20878554
[TBL] [Abstract][Full Text] [Related]
6. EPHA3 as a novel therapeutic target in the hematological malignancies.
Keane N; Freeman C; Swords R; Giles FJ
Expert Rev Hematol; 2012 Jun; 5(3):325-40. PubMed ID: 22780212
[TBL] [Abstract][Full Text] [Related]
7. Expression patterns of costimulatory molecules on cells derived from human hematological malignancies.
Zheng Z; Takahashi M; Aoki S; Toba K; Liu A; Osman Y; Takahashi H; Tsukada N; Suzuki N; Nikkuni K; Furukawa T; Koike T; Aizawa Y
J Exp Clin Cancer Res; 1998 Sep; 17(3):251-8. PubMed ID: 9894758
[TBL] [Abstract][Full Text] [Related]
8. Cytogenetic polyclonality in hematologic malignancies.
Johansson B; Billström R; Broberg K; Fioretos T; Nilsson PG; Ahlgren T; Malm C; Samuelsson BO; Mitelman F
Genes Chromosomes Cancer; 1999 Mar; 24(3):222-9. PubMed ID: 10451702
[TBL] [Abstract][Full Text] [Related]
9. Patterns of hematological malignancies in Chernobyl clean-up workers (1996-2005).
Gluzman D; Imamura N; Sklyarenko L; Nadgornaya V; Zavelevich M; Machilo V
Exp Oncol; 2006 Mar; 28(1):60-3. PubMed ID: 16614710
[TBL] [Abstract][Full Text] [Related]
10. Circulating levels and clinical significance of soluble CD40 in patients with hematologic malignancies.
Hock BD; McKenzie JL; Patton NW; Drayson M; Taylor K; Wakeman C; Kantarjian H; Giles F; Albitar M
Cancer; 2006 May; 106(10):2148-57. PubMed ID: 16598754
[TBL] [Abstract][Full Text] [Related]
11. Patterns of hematological and non-hematological malignancies in bone marrow in a tertiary care hospital in Nepal--11 years study.
Ghartimagar D; Ghosh A; Narasimhan R; Talwar OP
Nepal Med Coll J; 2012 Sep; 14(3):187-92. PubMed ID: 24047012
[TBL] [Abstract][Full Text] [Related]
12. MicroRNA-155 in serum-derived extracellular vesicles as a potential biomarker for hematologic malignancies - a short report.
Caivano A; La Rocca F; Simeon V; Girasole M; Dinarelli S; Laurenzana I; De Stradis A; De Luca L; Trino S; Traficante A; D'Arena G; Mansueto G; Villani O; Pietrantuono G; Laurenti L; Del Vecchio L; Musto P
Cell Oncol (Dordr); 2017 Feb; 40(1):97-103. PubMed ID: 27761889
[TBL] [Abstract][Full Text] [Related]
13. Genome-wide copy number variation in sporadic amyotrophic lateral sclerosis in the Turkish population: deletion of EPHA3 is a possible protective factor.
Uyan Ö; Ömür Ö; Ağım ZS; Özoğuz A; Li H; Parman Y; Deymeer F; Oflazer P; Koç F; Tan E; Özçelik H; Başak AN
PLoS One; 2013; 8(8):e72381. PubMed ID: 23991104
[TBL] [Abstract][Full Text] [Related]
14. Copy number variations of Interleukin-12B and T-bet are associated with systemic lupus erythematosus.
Yu B; Shao Y; Yue X; Zhang J; Guan M; Wan J; Zhang W
Rheumatology (Oxford); 2011 Jul; 50(7):1201-5. PubMed ID: 21278068
[TBL] [Abstract][Full Text] [Related]
15. KB004, a first in class monoclonal antibody targeting the receptor tyrosine kinase EphA3, in patients with advanced hematologic malignancies: Results from a phase 1 study.
Swords RT; Greenberg PL; Wei AH; Durrant S; Advani AS; Hertzberg MS; Jonas BA; Lewis ID; Rivera G; Gratzinger D; Fan AC; Felsher DW; Cortes JE; Watts JM; Yarranton GT; Walling JM; Lancet JE
Leuk Res; 2016 Nov; 50():123-131. PubMed ID: 27736729
[TBL] [Abstract][Full Text] [Related]
16. Dasatinib: a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia.
Steinberg M
Clin Ther; 2007 Nov; 29(11):2289-308. PubMed ID: 18158072
[TBL] [Abstract][Full Text] [Related]
17. Critical role of EphA3 in cancer and current state of EphA3 drug therapeutics.
London M; Gallo E
Mol Biol Rep; 2020 Jul; 47(7):5523-5533. PubMed ID: 32621117
[TBL] [Abstract][Full Text] [Related]
18. Matrix metalloproteinase production by bone marrow mononuclear cells from normal individuals and patients with acute and chronic myeloid leukemia or myelodysplastic syndromes.
Ries C; Loher F; Zang C; Ismair MG; Petrides PE
Clin Cancer Res; 1999 May; 5(5):1115-24. PubMed ID: 10353746
[TBL] [Abstract][Full Text] [Related]
19. Epigenetic inactivation of the miR-34a in hematological malignancies.
Chim CS; Wong KY; Qi Y; Loong F; Lam WL; Wong LG; Jin DY; Costello JF; Liang R
Carcinogenesis; 2010 Apr; 31(4):745-50. PubMed ID: 20118199
[TBL] [Abstract][Full Text] [Related]
20. Myeloid malignancies with acquired trisomy 21 as the sole cytogenetic change are clinically highly variable and display a heterogeneous pattern of copy number alterations and mutations.
Larsson N; Lilljebjörn H; Lassen C; Johansson B; Fioretos T
Eur J Haematol; 2012 Feb; 88(2):136-43. PubMed ID: 21933280
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
